P3.01-108 Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC
نویسندگان
چکیده
منابع مشابه
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC
INTRODUCTION In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (previously published). Here, we report EGFR mutation analyses of plasma-derived, circulating-free tumor DNA. METHODS Mandatory tumor and duplicate ...
متن کاملEGFR expression in NSCLC
E pidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is frequently overexpressed in nonsmall cell lung cancer (NSCLC). These receptors play an important role in tumour cell survival and activated phosphorylated EGFR results in the phosphorylation of downstream proteins that cause cell proliferation, invasion, metastasis, and inhibition of apoptosis. Expression appears to be dep...
متن کاملEGFR-TKI treatment and surgical resection for oligometastatic NSCLC?
not available, selection of patients for EGFR-TKI treatment can be based on patient-related factors, such as female gender, non-smoking status, Asian ethnicity, and adenoor bronchioloalveolar carcinoma histology. Such selection is associated with favourable responses in up to 30% of patients [5, 6]. The success of EGFR-TKIs in these subpopulations of NSCLC patients has been bittersweet. Certain...
متن کاملERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
Effects of estrogen receptorβ (ERβ) localization on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC) are unknown. First, we analyzed the relationship between ERβ localization determined by immunohistochemistry and EGFR-TKI outcomes in 184 patients with advanced NSCLC and found that ERβ expression localized in the cytoplasm an...
متن کاملBevacizumab in the treatment of NSCLC: patient selection and perspectives
Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed to extend survival of these patients, including antiangiogenic treatment. Vascular endothelial gro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2018
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2018.08.1669